T/CVDA 3-2022 Active Group standards

T/CVDA 3-2022 Animal Ebola virus neutralization antibody detection technology

Publish Date: 2022-07-19 Implement Date: 2022-07-25 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us

Price: $ 20.00

Download

Basic Information

Standard Code: T/CVDA 3-2022

Standard Type: Group standards

Standard Status: Active

is_force_gb: no

CCS Name: Agriculture, forestry

ICS Name: Veterinary medicine

Publish Date: 2022-07-19

Implement Date: 2022-07-25

Scope

Scope: This standard specifies the experimental operation methods and result determination criteria for the determination of neutralizing antibodies in animal Ebola virus serum. This standard is applicable to the qualitative detection and quantitative measurement of neutralizing antibodies against Ebola virus in animal serum. Main technical content: Ebola hemorrhagic fever (EHF) is an acute, febrile and severe hemorrhagic disease caused by Ebola virus (EBOV) infection, which is a highly lethal human-animal zoonotic disease. EBOV is one of the most lethal pathogens, with a mortality rate of up to 90% after infection. Since the outbreak of EHF in northeastern Zaire and southern Sudan in 1976, there have been multiple outbreaks to date. It is very important to develop serological methods for rapid identification of virus infection in order to take targeted treatment measures and prevent virus spread. This standard utilizes the reverse genetic operation system of vesicular stomatitis virus (VSV) to replace the glycoprotein gene GP of VSV with the glycoprotein gene GP of EBOV, and simultaneously express enhanced green fluorescent protein (EGFP), constructing an EGFP-expressing chimeric recombinant virus VSVΔG-EBOVGP-EGFP. The GP protein of EBOV is the only structural protein that induces the production of neutralizing antibodies. This recombinant virus VSVΔG-EBOVGP-EGFP expresses the GP protein of EBOV, which can specifically bind to and be neutralized by serum containing EBOV neutralizing antibodies, blocking virus infection. Currently, the detection of EBOV neutralizing antibodies is mainly carried out in biosafety level 4 laboratories using live EBOV, which is limited by experimental conditions and has high biosafety risks. Replacing live EBOV with VSVΔG-EBOVGP-EGFP for the detection of EBOV neutralizing antibodies can be operated in BSL-2 laboratories. This standard takes human or animal serum as the detection object, and uses the chimeric recombinant virus VSVΔG-EB